Among patients with diabetes who underwent PCI after an acute heart attack, those taking a GLP-1 had better survival rates ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Weight-loss drug patients experienced an effortless reduction in their alcohol intake within just four months of taking ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Novo Nordisk's CEO, who led its boom driven by obesity and diabetes medications only to see that success stall, is stepping ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

The president’s Middle East visit produced multibillion-dollar technology investments by the Saudis and Emiratis. But they ...

Former FDA Commissioner Dr. David Kessler has just released an important new book on diet and wieght loss. He spoke to Forbes about the latest research and issues.

Demand has soared for treatments targeting the less alluring effects of getting skinny quick. Make your appointment, stat!

Patients taking a GLP-1 for diabetes have a lower risk for AF at 3 years than those on other medications, report ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being ...

Losing weight after a years-long struggle, this letter writer gave credit to the method — then came the judgmental comments.